Table 1:

Demographic, clinical, and MRI findings of the patients with MS and the NCs included in the study

	NC (n = 28)	cMS (n = 35)	aMS (n = 57)
Age (years)	13.3 ± 2.8 (10–16)	13.2 ± 2.0 (8–16)	37.4 ± 7.2 (18–55)^a,^b
Age at onset (years)	n.a.	12.5 ± 1.8 (7–15)	36.9 ± 6.9 (18–54)^b
Patients with BOIgG	n.a	30 (85.7%)	51 (89.5%)
EDSS-baseline	n.a.	1.4 ± 0.8 (0–3.0)	3.2 ± 1.5 (1.0–7.0)^b
T2WMLV (cm³)	n.a.	4.0 ± 5.9 (0.2–27.5)	7.4 ± 9.4 (0.3–67.6)^b
Patients with CEL	n.a.	7 (20.0%)	12 (21.1%)
Number of CEL	n.a.	1.3 ± 0.4 (1–4)	1.1 ± 0.3 (1–3)
GMf-baseline %	53.9 ± 2.0(49.4–57.6)	53.0 ± 2.8(49.9–56.2)	49.9 ± 3.3(47.3–53.0)^a,^b
Patients with CLs	n.a.	12 (34.3%)	35 (61.4%)^b
CL number	n.a	2.1 ± 1.7 (1–12)	3.8 ± 2.6 (1–20)^b
CL volume (mm³)	n.a	240 ± 89 (0–745)	451 ± 125 (0–1250)^b

Note:—Data are reported as mean ± standard deviation (range).
BOIgG indicates immunoglobin G oligoclonal bands; n.a., not applicable; CEL, contrast-enhancing lesion.
↵a P < 0.001 (compared with NC).
↵b P < 0.001 (compared with cMS).